Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer/Lilly's Jardiance Wows With CVOT Data

This article was originally published in Scrip

Executive Summary

"Wonderful" and "profound" were just two of the adjectives thrown around at Sept. 17's symposium presentation of Boehringer Ingelheim and Eli Lilly & Co.'s EMPA-REG OUTCOMES study, the cardiovascular outcomes trial for their type 2 diabetes therapy Jardiance (empagliflozin), at the European Association for the Study of Diabetes.


Related Content

Heart Failure Pipeline Review: Amgen's Omecamtiv And Merck's Vericiguat Step Up To Plate
Jardiance's Label Expansion Will Change Diabetes Management
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
Lilly Executes Growth Strategy As New Products Drive Sales Gains


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts